戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d crizotinib, respectively, in patients with histiocytosis.
2 he self-limiting, cutaneous form of human LC histiocytosis.
3 d in this respect CCH differed from human LC histiocytosis.
4 iopsy may reveal hemophagocytosis and marrow histiocytosis.
5 orfman disease is a rare non-Langerhans cell histiocytosis.
6 ns in 14 of 18 (78%) patients with suspected histiocytosis.
7  survival in 156 adults with Langerhans cell histiocytosis.
8 for clinical trials of targeted therapies in histiocytosis.
9 em for the fields of ophthalmic oncology and histiocytosis.
10 lichiosis-induced hemophagocytic lymphocytic histiocytosis.
11 leiomyomatosis and pulmonary Langerhans cell histiocytosis.
12 Erdheim-Chester disease and Langerhans'-cell histiocytosis.
13 ster disease (ECD) is a rare, non-Langerhans histiocytosis.
14 ystemic viral infections and Langerhans cell histiocytosis.
15 ytic human diseases, such as Langerhans cell histiocytosis.
16  Erdheim-Chester disease and Langerhans cell histiocytosis.
17 gated in patients with malignant BRAF(V600E) histiocytosis.
18 taneous and progressive macrophage-dominated histiocytosis.
19 blastoma, some sarcomas, and Langerhans cell histiocytosis.
20 plant (UCBT) for refractory Langerhan's cell histiocytosis.
21 rapy to the entire spectrum of patients with histiocytosis.
22 g pneumonia), and pulmonary Langerhans' cell histiocytosis.
23 ine staging and diagnosis of Langerhans cell histiocytosis.
24 , Rosai-Dorfman 21, xanthogranuloma 7, mixed histiocytosis 11, Langerhans cell histiocytosis 15, and
25 a 7, mixed histiocytosis 11, Langerhans cell histiocytosis 15, and other 2) were examined.
26 lar xanthogranuloma (22%), 7 Langerhans cell histiocytosis (19%), 5 Rosai-Dorfman disease (14%), 5 xa
27 CSF transgenic mice developed a disseminated histiocytosis and had increased circulating IL-17 produc
28      Included among them are Langerhans cell histiocytosis and hemophagocytic lymphohistiocytosis.
29 anoma, conjunctival amyloidosis, and primary histiocytosis and in 1 case of ocular surface squamous n
30 , MEK inhibitor therapy led to resolution of histiocytosis and inflammation in a patient with H syndr
31 , we reveal the molecular pathway leading to histiocytosis and inflammation in this genetic disorder.
32                        Significant levels of histiocytosis and inflammation were observed in pressure
33 ing, establishing a novel pathway leading to histiocytosis and inflammation.
34 presence of distinct kinase mutations in the histiocytosis and myeloid neoplasm resulted in discordan
35 erature outlining the recent advancements in histiocytosis and ocular oncology was reviewed and combi
36 s revolutionized cancer treatment, including histiocytosis and ophthalmic oncology.
37 ogic and molecular landscape of ALK-positive histiocytosis and provides guidance for the clinical man
38 se, characterized by short stature, familial histiocytosis and sinus histiocytosis with massive lymph
39 ed with Erdheim-Chester disease (ECD) (mixed histiocytosis) and discuss the significance of this asso
40  chain proximal tubulopathy, crystal-storing histiocytosis, and crystalglobulinemia.
41      CD4 expression is prevalent in human LC histiocytosis, and in this respect CCH differed from hum
42 LC] proximal tubulopathy, LC crystal-storing histiocytosis, and LC crystalline podocytopathy) and les
43 ted with tuberous sclerosis, Langerhans cell histiocytosis, and lymphocytic interstitial pneumonia.
44 leiomyomatosis and pulmonary Langerhans cell histiocytosis are perhaps more frequently seen in the cl
45  cysts of Rathke's pouch and Langerhans cell histiocytosis, as well as with genetic neurodevelopmenta
46 e have developed a model for Langerhans cell histiocytosis comprising a CD1a-positive subcutaneous xe
47           The thickened choroid decreases on histiocytosis-directed (kinase inhibitor) therapy and ma
48  mum significantly decreased (P = 0.0016) on histiocytosis-directed (kinase inhibitor) therapy.
49 that secondary outcome was change in SFCT on histiocytosis-directed (kinase inhibitor) therapy.
50 s of 91 patients (46 males, 45 females) with histiocytosis (Erdheim-Chester 35, Rosai-Dorfman 21, xan
51 iocytic disorders, including Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfma
52 linical importance of evaluating adults with histiocytosis for a concomitant myeloid neoplasm.
53 functional evidence of the cell of origin of histiocytosis from actual patient materials has long bee
54                         Generalized eruptive histiocytosis (GEH) is a rare non-Langerhans cell histio
55       In this cohort, 19.8% of patients with histiocytosis had clinically evident infiltration of the
56   Furthermore, the majority of patients with histiocytosis had increased SFCT compared with age- and
57                Notably, 69% of patients with histiocytosis had SFCT >275 mum compared with 27% in con
58 n SLC29A3 cause H syndrome, characterized by histiocytosis, hyperinflammation, and immunodeficiency.
59                                     The term histiocytosis identifies a group of disorders characteri
60                         Generalized eruptive histiocytosis in association with a myeloid neoplasm may
61 r and molecular basis for the development of histiocytosis in several human syndromes associated with
62 igotes were not observed in organs but sinus histiocytosis in the spleen and lymphoid hyperplasia wer
63 or CD34(+) cells to drive the development of histiocytosis in xenotransplantation assays in vivo.
64 the prognosis and staging of Langerhans cell histiocytosis, in a human setting.
65                              Crystal storing histiocytosis is a rare disorder associated with monoclo
66                                 ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm
67 future radioimmunotherapy of Langerhans cell histiocytosis is also discussed.
68                   Pulmonary Langerhans'-cell histiocytosis is an uncommon interstitial lung disease i
69                              Langerhans cell histiocytosis is characterized by the abnormal clonal pr
70 al of adults with pulmonary Langerhans'-cell histiocytosis is shorter than that in the general popula
71  observed in 57% of cases of Langerhans cell histiocytosis (LCH) and 54% of cases of Erdheim-Chester
72 RAF mutation in a child with Langerhans cell histiocytosis (LCH) and demonstrate that the encoded pro
73                              Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) ar
74                              Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) ar
75 he most common histiocytoses-Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD)-wh
76 ved in half of patients with Langerhans cell histiocytosis (LCH) and in 50% to 100% of patients with
77 iseases that mostly comprise Langerhans cell histiocytosis (LCH) and non-LCH.
78                              Langerhans cell histiocytosis (LCH) and the non-LCH neoplasm Erdheim-Che
79 wo girls were diagnosed with Langerhans cell histiocytosis (LCH) at the age of 16 and 7 months and de
80                              Langerhans cell histiocytosis (LCH) combines in one nosological category
81                              Langerhans cell histiocytosis (LCH) has a broad spectrum of clinical beh
82 ling pathway is activated in Langerhans cell histiocytosis (LCH) histiocytes, but only 60% of cases c
83 ractory, risk-organ-positive Langerhans cell histiocytosis (LCH) in 2005.
84  little data on treatment of Langerhans cell histiocytosis (LCH) in adults.
85                              Langerhans cell histiocytosis (LCH) is a clinically and histologically h
86                              Langerhans cell histiocytosis (LCH) is a clonal disorder with elusive et
87                              Langerhans cell histiocytosis (LCH) is a clonal hematopoietic disorder d
88                              Langerhans cell histiocytosis (LCH) is a disorder characterized by an ab
89                              Langerhans cell histiocytosis (LCH) is a myeloid neoplasia, driven by sp
90                              Langerhans cell histiocytosis (LCH) is a myeloid neoplastic disorder dri
91                              Langerhans cell histiocytosis (LCH) is a myeloproliferative disorder cha
92                              Langerhans cell histiocytosis (LCH) is a potentially fatal condition cha
93                              Langerhans cell histiocytosis (LCH) is a rare disease affecting people o
94                              Langerhans cell histiocytosis (LCH) is a rare disease characterized by h
95                              Langerhans cell histiocytosis (LCH) is a rare disease with an unknown et
96                              Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm assoc
97                              Langerhans cell histiocytosis (LCH) is an enigmatic disease defined by t
98                              Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia
99                              Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia
100                              Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia
101                              Langerhans cell histiocytosis (LCH) is an inflammatory neoplastic disord
102                              Langerhans cell histiocytosis (LCH) is caused by clonal expansion of mye
103                              Langerhans cell histiocytosis (LCH) is characterized by inflammatory les
104                              Langerhans cell histiocytosis (LCH) represents a clonal proliferation of
105                              Langerhans-cell histiocytosis (LCH) results from the accumulation of tis
106 inal phenotype: for example, Langerhans cell histiocytosis (LCH) shares CD207(+) antigen with physiol
107 itive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated.
108 sis of patients with proven Langerhans' cell histiocytosis (LCH) was undertaken with the aim of evalu
109 olvement at presentation of Langerhans' cell histiocytosis (LCH) with subsequent disease course, surv
110 om skeletal collections with Langerhans Cell Histiocytosis (LCH), a benign osteolytic tumor-like diso
111 nterstitial pneumonia (DIP), Langerhans cell histiocytosis (LCH), and acute eosinophilic pneumonia (A
112                           In Langerhans cell histiocytosis (LCH), pathologic Langerhans cells (LCs) a
113                              Langerhans cell histiocytosis (LCH), previously known as histiocytosis X
114                           In Langerhans cell histiocytosis (LCH), the proliferating cell is the Lange
115  on a group of patients with Langerhans cell histiocytosis (LCH), which historically has poor disease
116                              Langerhans cell histiocytosis (LCH)-III tested risk-adjusted, intensifie
117 atening risk organs (ROs) in Langerhans cell histiocytosis (LCH).
118 ations have been observed in Langerhans cell histiocytosis (LCH).
119 itary axis, is documented in Langerhans cell histiocytosis (LCH).
120 ents were identified: 7 with Langerhans cell histiocytosis (LCH); 15 with Erdheim-Chester disease (EC
121                             "Langerhans cell histiocytosis" (LCH) describes a spectrum of clinical pr
122 eoside transporter, mutations in which cause histiocytosis-lymphadenopathy plus syndrome, a group of
123                           The historic term 'histiocytosis' meaning 'tissue cell' is used as a unifyi
124 ngerhans cell histiocytosis (so-called mixed histiocytosis [MH]), we identified an unexpected and her
125 ers are expanded in several LSDs, leading to histiocytosis of unknown pathophysiology.
126                                              Histiocytosis patients diagnosed with a concomitant myel
127 een identified previously in solid tumor and histiocytosis patients, caused hyperactivated MAP kinase
128 ed <18 years enrolled in the French National Histiocytosis Registry, 331 developed HI (median age at
129 who received transplants for Langerhans cell histiocytosis relative to other indications for transpla
130 ologic and molecular spectra of ALK-positive histiocytosis remain, however, poorly characterized.
131                                   Subtype of histiocytosis, sites of bone or central nervous disease,
132 ECD and ECD overlapping with Langerhans cell histiocytosis (so-called mixed histiocytosis [MH]), we i
133 ons) coexisting with those characteristic of histiocytosis (such as BRAFV600E and MAP2K1 mutations).
134  disease (ECD) is a rare non-Langerhans cell histiocytosis that most commonly affects adults and is d
135                             In patients with histiocytosis, the mean SFCT was 336.2 +/- 94.9 mum comp
136  Erdheim-Chester disease or Langerhans'-cell histiocytosis, the response rate was 43% (95% CI, 18 to
137 gically confirmed pulmonary Langerhans'-cell histiocytosis to ascertain their vital status and whethe
138 e describe the largest study of ALK-positive histiocytosis to date, with detailed clinicopathologic d
139  disease (ECD) is a rare non-Langerhans cell histiocytosis, to whose pathogenesis neoplastic and immu
140 o include neurodegeneration with bone marrow histiocytosis, visceromegaly, brown pancreas, and linkag
141 eneous, the phenotype of patients with mixed histiocytosis was closer to that of isolated ECD than to
142 , and diagnosis of a diffuse crystal storing histiocytosis was finally done.
143  the diagnosis of pulmonary Langerhans'-cell histiocytosis were analyzed with the Cox proportional-ha
144  risk factors, patients with Langerhans cell histiocytosis were at significantly increased risk for P
145 s from Langerhans cell sarcoma and malignant histiocytosis, which are hyperproliferative lesions typi
146  CCH is a localized form of self-limiting LC histiocytosis, which predominantly expresses an epiderma
147                 For the 50% of patients with histiocytosis who have BRAF(V600) mutations(3-5), RAF in
148 ocytosis (GEH) is a rare non-Langerhans cell histiocytosis with a benign, self-healing course.
149                                        Sinus histiocytosis with massive lymphadenopathy (SHML) is an
150 rt stature, familial histiocytosis and sinus histiocytosis with massive lymphadenopathy (SHML), chara
151 eim-Chester disease is a rare non-Langerhans histiocytosis with multisystem involvement.
152                                    Pulmonary histiocytosis X (PHX) is a diffuse, smoking-related lung
153 ell histiocytosis (LCH), previously known as histiocytosis X, is a reactive proliferative disease of
154 s with H syndrome are predisposed to develop histiocytosis, yet the mechanism is unclear.

 
Page Top